

## Technology Appraisal Committee A Interests Register

**Topic: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]**

**Publication Date: 17 December 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	TAC Committee Member	Financial Interests	Becky has undertaken private consultancy work for Pierre Fabre, for different drugs (not vinorelbine) in a different indication (not breast cancer).	09/09/2025	It was agreed that Becky Pennington's declaration would not prevent her from participating in discussions on this appraisal
Hugo Pedder	TAC Committee Member	Indirect Financial Interests	Hugo is employed by ConnectHEOR to do work for Roche on a technology and indication unrelated to the current appraisal, which will start later this week (post 07/10/2025)	07/10/2025	It was agreed that Hugo Pedder's declaration would not prevent him from participating in discussions on this appraisal
Zoe Philips	TAC Committee Member	Financial Interests	Zoe has provided consultancy to the company for this product in this indication	11/09/2025	It was agreed that Zoe Philips' declaration would prevent her from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Min Ven Teo	TAC Committee Member	Financial Interests	Employer receives grant from Daichii Sankyo for AF case finding work	15/09/2025	It was agreed that Min Ven Teo's declaration would not prevent him from participating in discussions on this appraisal
Nicole Droste	Patient Expert	Non-Finacial	Volunteer for patient advocacy charity Metupuk	07/10/2025	It was agreed that Nicole Droste's declaration would not prevent her from providing expert advice to the committee.